Vivos Therapeutics narrows Q3 net loss to $2.0 million as revenue rises 24% sequentially
GlobeNewswire · · AI-summarised by FinFlash
Vivos Therapeutics reported third-quarter revenue of $6.4 million, down from $6.8 million a year earlier but up 24% from $5.2 million in the second quarter. Net loss narrowed to $2.0 million, or 7 cents a share, from $5.4 million, helped by about $2.9 million of other income from reversing an Employee Retention Credit liability. Operating expenses fell 17% to $7.2 million. The company regained Nasdaq equity compliance but faces a December 2 bid-price deadline.
So What?
The improved loss is flattered by a one-off credit; the looming Nasdaq bid-price deadline raises the prospect of a reverse split for VVOS.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.